Companies / COV

CLEO DIAGNOSTICS LTD

ASX:COVPharmaceuticals, Biotechnology & Life Sciences
137.1M shares on issueASX (delayed) · as of 28 July 2026$0.34price · delayed$45.2Mmarket cap · indicative
D
Dilution grade

Share count grew 68% in 24 months; runway 2–4 quarters; options/rights overhang 22% of shares

Cash runway3.6 quarters of funding
Share-count growth (24m)68.0%
Raise cadence (24m)1 cash raise
Options & rights overhang22.5% of shares
In-the-money supply10.0% of shares
Pending proposed issuesnone

CLEO DIAGNOSTICS LTD's ordinary share count grew 68.0% between June 2024 and May 2026, to 137M shares. The company raised capital once in the 24‑month window for total proceeds of A$5.0M, most recently in December 2025 for A$5.0M. Options and rights on issue could convert into 31M new shares, equal to 22.5% of the current share count, of which 10% are in the money at the current share price; the nearest expiry is August 2026. At the March 2026 quarter the company reported A$5.7M in cash, covering 3.6 quarters at recent spending rates. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
22.5%
Max option dilution
10.0%
ITM option dilution
1
Raises · last 12 months
3.6 qtrs
Cash cover · 2–4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 137.1M per ASX (delayed) (28 July 2026).
130.3M132.8M135.3MDec 24Sept 25July 26Cash raise · 16 Dec 2025

Cash runway

3.6 qtrs
Two to four quarters of funding at the recent spend rate.
$5.7M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
28 May 20262A · quoted issueCOV : ORDINARY FULLY PAID137.1MAppendix 2A
29 Dec 20253G · unquotedCOV : ORDINARY FULLY PAID128.5MAppendix 3G
29 Dec 20252A · quoted issueCOV : ORDINARY FULLY PAID128.5MAppendix 2A
29 Dec 20252A · quoted issueCOV : ORDINARY FULLY PAID136.8MAppendix 2A
19 Sept 20252A · quoted issueCOV : ORDINARY FULLY PAID128.5MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 1 in the last 12 months

$5.0M
Capital raise
16 Dec 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

22.5%
Total overhang · of current shares
10.0%
In the money · at current price
30.8M
Potential new shares
Aug 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
3 July 2026Lucinda Joan FrawleyOther—1.5M—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

12 July 2026$PCLEO Enters Analytical Validation Phase
7 July 2026Change in Director's Interest Notice
28 May 2026Cleansing Notice
28 May 2026Application for quotation of securities - COV
19 May 2026$PCLEO Establishes U.S. Reimbursement Pathway
28 Apr 2026$PQuarterly activities and cashflow report
27 Apr 2026$PCLEO Commences Kit Manufacturing Ahead of FDA Submission
30 Mar 2026$PSample Collection Completion for Pivotal US Clinical Trial
22 Mar 2026$PCLEO Optimises Biomarker Panel Ahead of FDA Submission
25 Feb 2026$PAppendix 4D and Half Yearly Accounts
17 Feb 2026$PCLEO Confirms Next-Gen Platform for Ovarian Cancer Test
28 Jan 2026$PQuarterly activities and cashflow report
5 Jan 2026Ceasing to be a substantial holder
29 Dec 2025Chairman's End of Year Letter to Shareholders
29 Dec 2025Cleansing Notice
29 Dec 2025Notification regarding unquoted securities - COV
29 Dec 2025Application for quotation of securities - COV
29 Dec 2025Application for quotation of securities - COV
17 Dec 2025Proposed issue of securities - COV
17 Dec 2025$PCLEO Raises $5m to Support U.S. Market Launch

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.